Metformin protects against small intestine damage induced by diabetes and dunning’s prostate cancer: A biochemical and histological study
Journal of Molecular Histology · 2024
DOI: 10.1007/s10735-024-10252-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Histology, 2024. Verfasst von Eda Dagsuyu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Engineering, Istanbul University-Cerrahpaşa, Istanbul, Türkiye. eda.dagsuyu@iuc.edu.tr. Hauptthemen laut MEDLINE: Metformin, Intestine, Small, Prostatic Neoplasms, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The oral biguanide metformin is used to treat type 2 diabetic mellitus (T2DM). Anti-cancer effects have been proven by metformin in different hormone-sensitive tumors, including breast, pancreatic, colon, and prostate cancer. Therefore, we investigated whether metformin could defend against small intestine damage in Dunning's prostate cancer. The study divided the six groups of male Copenhagen rats into the following categories: control, diabetic (D), cancer (C), diabetic + cancer (DC), cancer + metformin (CM), and diabetic + cancer + metformin (DCM). After sacrifice, the small intestines were removed to assess biochemical markers and histopathological evaluation. Biochemical evaluations showed that glutathione (reduced) levels and other enzyme activities related antioxidant systems, paraoxonase, sodium potassium ATPase, acetylcholinesterase activities were decreased. In contrast, lipid peroxidation, total oxidant status, reactive oxygen species, interleukin-1β, interleukin-6, tumor necrosis factor-α, sucrase, maltase, trypsin, myeloperoxidase, xanthine oxidase activities, protein carbonyl contents and sialic acid levels were raised in the damaged groups. Treatment with metformin restored all of this. The histological assessment revealed moderate to severe damage in the small intestine following processes D and C. According to the study's findings, metformin treatment led to a notable decline in histopathological damage in the C and DC. A slight lowering in inflammatory cells and an improvement in the damaged gland integrity in the small intestine were noted with metformin treatment. Metformin use protected the small intestinal tissue damage and decreased oxidative stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Faculty of Engineering, Istanbul University-Cerrahpaşa, Istanbul, Türkiye. eda.dagsuyu@iuc.edu.tr.
- Department of Histology and Embryology, Faculty of Medicine, Halic University, Istanbul, Türkiye.
- Department of Biology, Faculty of Science, Istanbul University, Istanbul, Türkiye.
- Department of Chemistry, Faculty of Engineering, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.
Zitieren
APA
Dagsuyu, E., Koroglu, P., Bulan, O. K., Gul, I. B., & Yanardag, R. (2024). Metformin protects against small intestine damage induced by diabetes and dunning’s prostate cancer: A biochemical and histological study. Journal of Molecular Histology. https://doi.org/10.1007/s10735-024-10252-y
Vancouver
Dagsuyu E, Koroglu P, Bulan OK, Gul IB, Yanardag R. Metformin protects against small intestine damage induced by diabetes and dunning’s prostate cancer: A biochemical and histological study. Journal of Molecular Histology. 2024. doi:10.1007/s10735-024-10252-y
BibTeX
@article{Dagsuyu2024,
author = {Dagsuyu, Eda and Koroglu, Pinar and Bulan, Omur Karabulut and Gul, Ilknur Bugan and Yanardag, Refiye},
title = {Metformin protects against small intestine damage induced by diabetes and dunning’s prostate cancer: A biochemical and histological study},
journal = {Journal of Molecular Histology},
year = {2024},
doi = {10.1007/s10735-024-10252-y}
}
EUVIMED